Medicine guide

Pazopanib Accord

On the Bulgarian pack: Пазопаниб Акорд 200 mg филмирани таблетки

200 mg · film-coated tablets

  • Prescription only
  • Cancer treatments and immune-system medicines
Active substance
Pazopanib
Made by
Accord Healthcare Polska Sp. z.o.o.

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Medicine groupCancer treatments and immune-system medicinesL01EX03

Mediclarum has not yet read the official leaflet for this product. The exact uses and dose are in the leaflet inside the pack. Open the official leaflet

How it works

This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (pazopanib). It describes the substance, not this Bulgarian product — its uses and doses can differ.

In vitro, pazopanib inhibited ligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-β receptors.

In vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis in a mouse model, and the growth of some human tumor xenografts in mice.

Half-life31 h
Mostly cleared after≈ 6 daysfive half-lives — our arithmetic
How the body breaks it down

In vitro studies demonstrated that pazopanib is metabolized by CYP3A4 with a minor contribution from CYP1A2 and CYP2C8.

With food

Effect of Food Systemic exposure to pazopanib is increased when administered with food.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-01-19

Safety of the active substance

This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (pazopanib). It describes the substance, not this Bulgarian product — its uses and doses can differ.

Serious warning

WARNING: HEPATOTOXICITY Severe and fatal hepatotoxicity has been observed in clinical trials.

Most common side effects

The most common adverse reactions in patients with STS (≥ 20%) are fatigue, diarrhea, nausea, decreased weight, hypertension, decreased appetite, vomiting, tumor pain, hair color changes, musculoskeletal pain, headache, dysgeusia, dyspnea, and skin hypopigmentation.

Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

European UnionNo exact match for this strength and form

SwitzerlandNo exact match for this strength and form

Details

Made byAccord Healthcare Polska Sp. z.o.o. · Poland
Active substancePazopanib
Used inCancer treatments and immune-system medicines
Strength200 mg
Formfilm-coated tablets
Pack sizes10 · 30 · 60 · 90
ClassificationL01EX03 · Cancer treatments and immune-system medicines
Name in the registerПазопаниб Акорд 200 mg филмирани таблетки
Reg. no.20240046

Source: Bulgarian Drug Agency register · 2026-08-01 · not reviewed by a clinician

Източник: Изпълнителна агенция по лекарствата (ИАЛ). The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.

Other strengths and forms

2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

  • film-coated tablets2 products

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.